Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review

Journal of Cancer Research and Therapeutics

Volumn 6, Issue 1, 2010, Pages 31-35

  Weide, Rudolf ^a   Köppler, Hubert ^a   Antras, Lucia ^b   Smith, Michael ^b   Eva Chang, M P H ^b   Green, Jesse ^b   Wintfeld, Neil ^b   Neary, Maureen ^b   Duh, Mei ^b  

^a Praxisklinik fur Hamatologie und Onkologie   (Germany)

^b ANALYSIS GROUP   (United States)

Author keywords

Ibandronate; Multiple myeloma; Renal impairment; Zoledronic acid

Indexed keywords

CREATININE; IBANDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; GERMANY; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; JAW OSTEONECROSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEPHROTOXICITY; PROTEINURIA; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMIDAZOLES; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 77952646938     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.63570     Document Type: Article

References (27)

1. Sporn JR, McIntyre OR. Chemotherapy of previously untreated multiple myeloma patients: An analysis of recent treatment results. Semin Oncol 1986;13:318-25.
2. Bergsagel DE. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? Eur J Cancer Clin Oncol 1989;25:159-61.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
4. Shipman CM, Oyajobi BO, Mundy GR. Advances in the management of myeloma bone disease. Expert Opin Pharmacother 2005;6:2781-91.
5. Coleman RE. Metastatic bone disease: Clinical features, patho physiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
6. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc 1975;50:29-40.
7. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405.
8. Body JJ, Kanis J, Diel I, Bergström B. Risk reductions in metastatic breast cancer: Multivariate poisson regression analyses of oral and i.v. ibandronate. J Clin Oncol2003;22:46.
9. Body JJ, Diel IJ, Lichinitzer MR, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:1133-7.
10. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-21.
11. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003;349:1676-9.
12. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003;64:281-9.
13. Johnson KB, Gable P, Kaime EM, Luiken G, Castillos T, Hu J. Significant deterioration in renal function with the new bisphosphonate zoledronic acid. J Clin Oncol2003;22:738.
14. Mazj S, Lichtman SM. Renal dysfunction associated with bisphosphonate use: Retrospective analysis of 293 patients with respect to age and other clinical characteristics. J Clin Oncol2004;22:735.
15. Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, et al. Zoledronic Acid and renal toxicity: Data from French adverse effect reporting database. Ann Pharmacother 2005;39:1194-7.
16. ® (zoledronic acid). EU summary of product characteristics. Basel, Switzerland: Novartis International AG; 2005.
17. ® (zoledronic acid). US summary of product characteristics. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2004.
18. Pecherstorfer M, Rivkin S, Body JJ, Diel I, Bergstrom B. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: An open-label trial. Clin Drug Investig 2006;26:315-22.
19. F. Hoffmann-La Roche Ltd. Bondronat (ibandronate acid). Summary of product characteristics. Basel, Switzerland: F. Hoffmann-La Roche Ltd; 2003.
20. st ESMO Congress; September 29-October 3, 2006; Istanbul, Turkey.
21. Levey AS, Bosch J P, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
22. Andersen PK, Gill RD. Cox's regression model for counting processes: A large sample study. Ann Statist 1982;10:1100-20.
23. Thadhani R, Pascual M, Bonventre J V. Acute renal failure. N Engl J Med 1996;334:1448-60.
24. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7.
25. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44.
26. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68.
27. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer 2007;110:1376-84.